Document Detail


Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia.
MedLine Citation:
PMID:  2449026     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Compared to single-agent therapy with hydroxyurea or myleran (155 patients), intensive chemotherapy with vincristine, cytosine arabinoside, prednisone and cyclophosphamide (60 patients) or anthracyclines (37 patients) showed significant survival improvement overall (p less than 0.01) and among intermediate- and high-risk patients. Of 51 patients treated with human leukocyte alpha interferon (IFN-alpha), 36 (71%) had complete hematologic remission (CHR); 20 patients (39%) showed Ph suppression which was persistent in 13 for greater than 21 months. Survival was better in patients obtaining remission with IFN-alpha. Recombinant gamma interferon (IFN-gamma) was also active in chronic myelogenous leukemia. Therapy with combined IFN-alpha + IFN-gamma has been initiated. Compared to the expected survival, the observed survival is favorable for IFN-alpha and the combined chemotherapy and IFN-alpha programs. Future therapeutic trials will incorporate initial IFN therapy followed by cyclic intensive chemotherapy at 6-month intervals and IFN maintenance between chemotherapy cycles.
Authors:
H M Kantarjian; M Talpaz; R Kurzrock; M J Keating; K B McCredie; J Gutterman; E J Freireich
Related Documents :
7544996 - Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cyt...
9816086 - Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovati...
8610636 - 5-fluorouracil and alpha-interferon in hepatocellular carcinoma.
17538086 - Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
16445646 - Unilateral groin and pelvic irradiation for unilaterally node-positive women with vulva...
12756096 - Histopathologic recognition of involved margins of lentigo maligna excised by staged ex...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Acta haematologica     Volume:  78 Suppl 1     ISSN:  0001-5792     ISO Abbreviation:  Acta Haematol.     Publication Date:  1987  
Date Detail:
Created Date:  1988-03-08     Completed Date:  1988-03-08     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0141053     Medline TA:  Acta Haematol     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  70-4     Citation Subset:  IM    
Affiliation:
Department of Hematology, M.D. Anderson Hospital and Tumor Institute, Houston, Tex.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Busulfan / therapeutic use*
Cyclophosphamide / administration & dosage
Cytarabine / administration & dosage
Drug Evaluation
Humans
Hydroxyurea / therapeutic use*
Interferons / administration & dosage,  adverse effects,  therapeutic use*
Leukemia, Myeloid / drug therapy*
Prednisone / administration & dosage
Recombinant Proteins / adverse effects,  therapeutic use
Retrospective Studies
Vincristine / administration & dosage
Grant Support
ID/Acronym/Agency:
CA28153/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 127-07-1/Hydroxyurea; 147-94-4/Cytarabine; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 55-98-1/Busulfan; 57-22-7/Vincristine; 9008-11-1/Interferons

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Axillary hyperhidrosis. Local treatment with aluminium-chloride hexahydrate 25% in absolute ethanol ...
Next Document:  Histamine release from basophil leukocytes in asthma patients after in vitro provocation with variou...